FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2022
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca to acquire Neogene Therapeutics
29 November 2022 7:00 GMT
AstraZeneca to acquire Neogene Therapeutics,
accelerating ambition in Oncology cell therapy
Acquisition provides access to next-generation T-cell
receptor
therapies with promising potential for targeting solid
tumours
AstraZeneca today announced an agreement to acquire Neogene
Therapeutics Inc. (Neogene), a global clinical-stage biotechnology
company pioneering the discovery, development and manufacturing of
next-generation T-cell receptor therapies (TCR-Ts) that offer a
novel cell therapy approach for targeting cancer.
With a shared goal of bringing cell therapies to patients with
solid tumours, Neogene's expertise in TCR-T discovery, development
and manufacturing will strengthen AstraZeneca's ambition to
transform outcomes for patients.
TCR-Ts are emerging as a promising therapeutic modality in
cancer treatment. Most current cell therapy approaches in
oncology focus on modifying the immune system's T cells to
recognise proteins expressed on the surface of cancer cells. In
contrast, TCR-Ts can recognise intracellular targets, including
cancer-specific mutations, thereby potentially unlocking targets
previously inaccessible using cell therapies.
Susan Galbraith, Executive Vice President, Oncology R&D,
AstraZeneca, said: "This acquisition represents a unique
opportunity to bring innovative science and leading experts in
T-cell receptor biology and cell therapy manufacturing together
with our internal oncology cell therapy team, unlocking new ways to
target cancer. Neogene's leading TCR discovery capabilities
and extensive manufacturing experience complement the cell therapy
capability we have built over the last three years and allow us to
accelerate the development of potentially curative cell therapies
for the benefit of patients."
Carsten Linnemann, PhD, Chief Executive Officer, Neogene, said: "We
are excited to work together with AstraZeneca towards our shared
mission of transforming the treatment options for patients with
solid tumours using next-generation T-cell receptor therapies. Our
expertise, clinical portfolio and platform technologies in this
area combined with AstraZeneca's leadership in oncology and global
footprint mean we are well-positioned to translate pioneering
science into novel treatments for hard-to-treat
cancers."
Neogene will operate as a wholly owned subsidiary of AstraZeneca,
with operations in Amsterdam, the Netherlands and California,
US.
Financial considerations
AstraZeneca will acquire all outstanding equity of Neogene for a
total consideration of up to $320m, on a cash and debt free basis.
This will include an initial payment of $200m on deal closing, and
a further up to $120m in both contingent milestones-based and
non-contingent consideration.
The transaction is expected to close in the first quarter of 2023,
subject to customary closing conditions and regulatory clearances.
The transaction does not impact AstraZeneca's financial guidance
for 2022.
Notes
Neogene Therapeutics
Neogene Therapeutics, Inc. is a global biotechnology company
focused on discovering, developing and manufacturing
next-generation, transformative TCR therapies targeting neoantigens
in solid cancers. Neogene is advancing a pipeline of fully
individualized TCR therapies as well as TCR therapies targeting
shared neoantigens, including mutated KRAS (mKRAS) and mutated TP53
(mTP53).
Neogene was founded by Carsten Linnemann, PhD, Chief Executive
Officer of Neogene, and Ton Schumacher, PhD, Principal Investigator
at the Netherlands Cancer Institute, Oncode Institute in
partnership with Two River, and cell therapy industry veteran Arie
Belldegrun, MD, founder of Kite Pharma, Inc. and Co-Founder and
Executive Chairman of Allogene Therapeutics, Inc. as well as key
investments from Vida Ventures, TPG, EcoR1 Capital, Jeito Capital,
Syncona, Polaris Partners and Pontifax.
Neogene has EU headquarters in Amsterdam and US headquarters in
Santa Monica. Its team has deep gene and cell therapy expertise and
a shared mission to bring next-generation transformative TCR
therapies to patients with solid cancers worldwide. Please
visit www.neogene.com and
follow Neogene on LinkedIn.
AstraZeneca in oncology cell therapy
AstraZeneca is building a cell therapy portfolio that aims to
empower and equip the immune system's T cells to more effectively
fight cancer. The Company is building on the work already done in
blood cancers where chimeric antigen receptor T-cell (CAR-T)
therapies, a
type of living medicine created by isolating and modifying a
patient's T cells to target their specific
tumour, are
being used to treat some haematological malignancies. Their
research teams are exploring new ways to target and arm CAR-Ts to
increase their effectiveness in solid tumours by overcoming the
immune-suppressive tumour microenvironment. Looking to the future,
AstraZeneca is working to engineer next-generation cell therapies,
where physicians could potentially select from a library of
off-the-shelf patient-ready therapies already developed from the
cells of healthy donors.
Ultimately, by utilising innovative strategies to improve the
precision and effectiveness of cell therapies, the Company's goal
is to deliver new medicines to help transform the lives of patients
living with a range of cancers.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition
to provide cures for cancer in every form, following the science to
understand cancer and all its complexities to discover, develop and
deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It
is through persistent innovation that AstraZeneca has built one of
the most diverse portfolios and pipelines in the industry, with the
potential to catalyse changes in the practice of medicine and
transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day,
eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
29 November 2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
AstraZeneca (NYSE:AZN)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
